Literature DB >> 11562287

Antagonists of the Src homology 2 (SH2) domains of Grb2, Src, Lck and ZAP-70.

C García-Echeverria1.   

Abstract

Src homology 2 (SH2) domains are protein modules that mediate intracellular protein-protein interactions in signal transduction pathways. The specific association of an SH2 domain with a phosphotyrosine-containing sequence of another protein induces a cascade of molecular interactions that effect a wide range of cellular processes. Alterations in these signaling pathways have been associated with the development and progression of a broad range of pathologies. Because of the regulatory role of SH2 domains in these signal transduction pathways, specific SH2 domains can be ideal targets for intervention with therapeutic agents in many different disease indications (e.g. cancer, osteoporosis, disorders of the immune and cardiovascular systems). Among the SH2 domains pursued as drug discovery targets in the last few years are those of Grb2, Src, Lck and ZAP-70. This review focuses on contributions in the design and synthesis of antagonists of these particular SH2 domains. Specific examples have been selected to illustrate how structure-based design approaches have been used to progress in this area of research.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11562287     DOI: 10.2174/0929867013371905

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  9 in total

1.  Peptide bicycles that inhibit the Grb2 SH2 domain.

Authors:  Justin S Quartararo; Pianpian Wu; Joshua A Kritzer
Journal:  Chembiochem       Date:  2012-06-11       Impact factor: 3.164

Review 2.  Improved approach to identify cancer-associated autoantigens.

Authors:  Félix Fernández Madrid; Naimei Tang; Huda Alansari; Robert L Karvonen; John E Tomkiel
Journal:  Autoimmun Rev       Date:  2004-12-13       Impact factor: 9.754

Review 3.  Targeting SH2 domains in breast cancer.

Authors:  Pietro Morlacchi; Fredika M Robertson; Jim Klostergaard; John S McMurray
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

4.  A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain.

Authors:  John Wojcik; Oliver Hantschel; Florian Grebien; Ines Kaupe; Keiryn L Bennett; John Barkinge; Richard B Jones; Akiko Koide; Giulio Superti-Furga; Shohei Koide
Journal:  Nat Struct Mol Biol       Date:  2010-03-28       Impact factor: 15.369

Review 5.  Grb2 signaling in cell motility and cancer.

Authors:  Alessio Giubellino; Terrence R Burke; Donald P Bottaro
Journal:  Expert Opin Ther Targets       Date:  2008-08       Impact factor: 6.902

6.  A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.

Authors:  Edmond J Auzenne; Jim Klostergaard; Pijus K Mandal; Warren S Liao; Zhen Lu; Fengqin Gao; Robert C Bast; Fredika M Robertson; John S McMurray
Journal:  J Exp Ther Oncol       Date:  2012

Review 7.  Development of extracellular signal-regulated kinase inhibitors.

Authors:  Kimberly Burkhard; Sarice Smith; Rahul Deshmukh; Alexander D MacKerell; Paul Shapiro
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

8.  Structure-affinity relationships of glutamine mimics incorporated into phosphopeptides targeted to the SH2 domain of signal transducer and activator of transcription 3.

Authors:  Pijus K Mandal; Zhiyong Ren; Xiaomin Chen; Chiyi Xiong; John S McMurray
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

9.  Development of Grb2 SH2 Domain Signaling Antagonists: A Potential New Class of Antiproliferative Agents.

Authors:  Terrence R Burke
Journal:  Int J Pept Res Ther       Date:  2006-03-14       Impact factor: 1.931

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.